CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trialJia Liu, Lin Shen, Jinbo Yue et al.|Nature Medicine|2025Cited by 29
Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: 
Safety, Efficacy, and BiomarkersYakun Wang, Lin Shen, Tianshu Liu et al.|The Oncologist|2022Cited by 15